An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation

Publication date: Available online 25 January 2017
Source:Radiotherapy and Oncology
Author(s): Radhika Patel, Holly E. Barker, Joan Kyula, Martin McLaughlin, Magnus T. Dillon, Ulrike Schick, Hind Hafsi, Alan Thompson, Vincent Khoo, Kevin Harrington, Shane Zaidi
PurposeChk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities.Materials and methodsWe characterized the radiosensitizing activity of CCT244747, the first orally bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo models.ResultsCCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in cancer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of the radiation-induced G2 arrest and premature entry into mitosis.ConclusionsCCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination with radiotherapy.



http://ift.tt/2jt5wMs